Autres langues Alzamend Neuro, Inc.

Actions

ALZN

US02262M6057

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 28/08/2026			Varia. 5j.	Varia. 1 janv.
1,660 ^USD	-0,30%		+6,41%	-8,79%

20/08	Alzamend Neuro annonce l'acceptation de ses résultats d'IRMf au repos pour AL001 pour une présentation par affiche lors de Neuroscience 2026	CI
18/08	Alzamend Neuro, Inc. présente les données d'imagerie du lithium de phase 1/2A pour l'AL001 lors d'un atelier de l'ISMRM	CI

Autres langues

20/08	Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
20/08	Alzamend Neuro Reports Resting-State Fmri Findings For Al001 Accepted For Poster Presentation At Neuroscience 2026
18/08	Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain
18/08	Alzamend Neuro, Inc. Reports Phase 1/2A Lithium Imaging Data For AL001 At ISMRM Workshop
04/08	Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
22/07	Alzamend Neuro : Annual Report for Fiscal Year Ending April 30, 2026 (Form 10-K)
22/07	Alzamend Neuro, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026
22/07	Alzamend Neuro, Inc. Auditor Raises 'Going Concern' Doubt
21/07	Alzamend Neuro, Inc. Announces Demise of Lynne Fahey Mcgrath, Director on July 20, 2026
07/04	Alzamend Neuro : Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
07/04	Alzamend Neuro, Inc. Reports Encouraging Pharmacodynamic Data From Phase II Clinical Trial Of AL001
26/03	Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
26/03	Alzamend Neuro, Inc. Reports Positive Topline Data From Phase II Clinical Trial of AL001
16/03	Alzamend Neuro Initiates Phase Ii Clinical Trial of Al001 Lithium in Brain Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
16/03	Alzamend Neuro initiates phase II clinical trial of AL001 "lithium in brain" study in patients with bipolar disorder in collaboration with Massachusetts General Hospital
16/03	Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
11/03	Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2026
06/03	Alzamend Neuro Inc enters ATM sales agreement to sell up to $3.0 million in common stock - SEC filing
09/12	Alzamend Neuro, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2025
19/11	Alzamend Neuro, Inc. Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 Lithium in Brain Study Conducted at Massachusetts General Hospital
19/11	Alzamend Neuro announces completion of clinical portion of phase II clinical trial of AL001 "lithium in brain" study conducted at Massachusetts General Hospital
19/11	Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital
18/11	Alzamend Neuro, Inc. Announces the Passing of Andrew H. Woo, M.D., Ph.D., Board Director on November 14, 2025
08/10/25	Alzamend Neuro Insider Sold Shares Worth $344,222, According to a Recent SEC Filing
10/09/25	Alzamend Neuro, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2025